Drug profile · INN
cefpodoxime proxetil
CEFPODOXIME PROXETIL
cefpodoxime proxetil (CEFPODOXIME PROXETIL) is a bacterial penicillin-binding protein inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — cefpodoxime proxetil
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 3
- Programs
- 1
- Data quality
- 0.84
Quick answer
cefpodoxime proxetil (CEFPODOXIME PROXETIL) is a bacterial penicillin-binding protein inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial penicillin-binding protein inhibitor
Primary target: Bacterial penicillin-binding protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 10500271
Compositions and methods for self-adjuvanting vaccines against microbes and tumors
granted -
US 10265394
Compositions and methods for self-adjuvanting vaccines against microbes and tumors
granted -
US 10238734
Compositions and methods for self-adjuvanting vaccines against microbes and tumors
granted
Frequently asked questions
What is cefpodoxime proxetil?
cefpodoxime proxetil (CEFPODOXIME PROXETIL) is a bacterial penicillin-binding protein inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for cefpodoxime proxetil?
CEFPODOXIME PROXETIL is a marketed brand name for cefpodoxime proxetil. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cefpodoxime proxetil?
cefpodoxime proxetil has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.